간편결제 가능보고서 주문 후, 연도 업데이트와 커스터마이징을 위해 당사에서 연락드릴 예정입니다.
상세 사항에 따라 가격이 변동될 수 있으니 참고 바랍니다.
기본 보고서는 영문으로 작성되며, PDF,PPT,DOCX(워드) 형식으로 제공 가능합니다.
보고서 전달 후에는 환불이 불가능하오니 양해 바랍니다.
평균 납기는 2주이며, 형식과 내용에 따라 달라질 수 있습니다.
요약
생물 제약 시장. 바이오 제약 시장 규모는 2019 년에 2,390 억 달러로 2022-2027 년 예측 기간 동안 13.28%의 CAGR로 증가합니다. 빠른 속도의 과학적 발전은 분자 수준에서 질병에 대한 통찰력을 높일 수 있습니다
Summary
Biopharmaceutical Market. The Biopharmaceutical Market size is $239.8 Billion in 2019, growing at a CAGR of 13.28% during the forecast period 2022-2027. The rapid pace of scientific advancements enables greater insight into diseases at the molecular level
Table of Contents
1. Biopharmaceutical Market Overview
1.1 Definitions and Scope
2. Biopharmaceutical Market Executive Summary
2.1 Marketrevenue, Market Size and Key Trends
2.2 Key trends by Product Type
2.3 Key trends by Therapeutic Application
2.4 Key trends by End Use
2.5 Key trends by Geography
3. Biopharmaceutical Market Landscape
3.1 MarketShare Analysis- Key Companies
3.2 Product Benchmarking- Key Companies
3.3 Financial Analysis - Key Companies
3.4 Patent Analysis
3.5 Pricing Analysis
4. Biopharmaceutical Market Forces
4.1 Market Drivers
4.2 Market Constraints/Challenges
4.3 Porters Five Force Model
4.3.1 Bargaining Power of Suppliers
4.3.2 Bargaining Powers of Customers
4.3.3 Threat of New Entrants
4.3.4 Rivalry Among Existing Players
4.3.5 Threat of Substitutes
5. Biopharmaceutical Market Strategic Analysis
5.1 Value Chain Analysis
5.2 Opportunities Analysis
5.3 Market Life Cycle
6. Biopharmaceutical Market – By Product Type (Market Size - $Million/$Billion)
6.1 Cell and Gene Therapies
6.2 Monoclonal Antibodies
6.3 Hormones
6.4 Vaccines
6.5 Enzymes
6.6 Blood Components
6.7 Cell and Gene Therapies
6.8 Growth Factors
6.9 Gene Therapies
6.10 Thrombolytics and Anticoagulants
6.11 Recombinant Protein
6.12 Others
7. Biopharmaceutical Market– By Therapeutic Application (Market Size - $Million/$Billion)
7.1 Oncology
7.2 Inflammatory Diseases
7.3 Cardiology
7.4 Neurology
7.5 Autoimmune Disorders
7.6 Metabolic Disorders
7.7 Hormonal Disorders
7.8 Others
8. Biopharmaceutical Market– By End Use (Market Size - $Million/$Billion)
8.1 Health and Care
8.2 Biopharmaceutical Companies
8.3 Diagnostic Labs
8.4 Clinical Research Institute
8.5 CROs
9. Biopharmaceutical Market- By Geography (Market Size - $Million/$Billion)
9.1 North America
9.1.1 U.S.
9.1.2 Canada
9.1.3 Mexico
9.2 Europe
9.2.1 U.K.
9.2.2 Germany
9.2.3 France
9.2.4 Italy
9.2.5 France
9.2.6 Netherlands
9.2.7 Spain
9.2.8 Rest of Europe
9.3 Asia-Pacific
9.3.1 China
9.3.2 Japan
9.3.3 South Korea
9.3.4 India
9.3.5 Australia & New Zealand
9.3.6 Rest of Asia-Pacific
9.4 Rest of the World
9.4.1 Middle East
9.4.2 Africa
9.4.3 South America
10. Biopharmaceutical Market Entropy
11. Biopharmaceutical Market Company Analysis
11.1 Company Revenue, Products, M&A, Developments
11.2 Company 1
11.3 Company 2
11.4 Company 3
11.5 Company 4
11.6 Company 5
11.7 Company 6
11.8 Company 7
11.9 Company 8
11.10 Company 9
11.11 Company 10
"*Financials for private companies would be provided on a best efforts basis”.
세금계산서 발행 문의
T. 070 8015 5940
보고서 주문 후, 연도 업데이트와 커스터마이징을 위해 당사에서 연락드릴 예정입니다.
상세 사항에 따라 가격이 변동될 수 있으니 참고 바랍니다.
기본 보고서는 영문으로 작성되며, PDF,PPT,DOCX(워드) 형식으로 제공 가능합니다.
보고서 전달 후에는 환불이 불가능하오니 양해 바랍니다.
평균 납기는 2주이며, 형식과 내용에 따라 달라질 수 있습니다.
요약
생물 제약 시장. 바이오 제약 시장 규모는 2019 년에 2,390 억 달러로 2022-2027 년 예측 기간 동안 13.28%의 CAGR로 증가합니다. 빠른 속도의 과학적 발전은 분자 수준에서 질병에 대한 통찰력을 높일 수 있습니다
Summary
Biopharmaceutical Market. The Biopharmaceutical Market size is $239.8 Billion in 2019, growing at a CAGR of 13.28% during the forecast period 2022-2027. The rapid pace of scientific advancements enables greater insight into diseases at the molecular level
Table of Contents
1. Biopharmaceutical Market Overview
1.1 Definitions and Scope
2. Biopharmaceutical Market Executive Summary
2.1 Marketrevenue, Market Size and Key Trends
2.2 Key trends by Product Type
2.3 Key trends by Therapeutic Application
2.4 Key trends by End Use
2.5 Key trends by Geography
3. Biopharmaceutical Market Landscape
3.1 MarketShare Analysis- Key Companies
3.2 Product Benchmarking- Key Companies
3.3 Financial Analysis - Key Companies
3.4 Patent Analysis
3.5 Pricing Analysis
4. Biopharmaceutical Market Forces
4.1 Market Drivers
4.2 Market Constraints/Challenges
4.3 Porters Five Force Model
4.3.1 Bargaining Power of Suppliers
4.3.2 Bargaining Powers of Customers
4.3.3 Threat of New Entrants
4.3.4 Rivalry Among Existing Players
4.3.5 Threat of Substitutes
5. Biopharmaceutical Market Strategic Analysis
5.1 Value Chain Analysis
5.2 Opportunities Analysis
5.3 Market Life Cycle
6. Biopharmaceutical Market – By Product Type (Market Size - $Million/$Billion)
6.1 Cell and Gene Therapies
6.2 Monoclonal Antibodies
6.3 Hormones
6.4 Vaccines
6.5 Enzymes
6.6 Blood Components
6.7 Cell and Gene Therapies
6.8 Growth Factors
6.9 Gene Therapies
6.10 Thrombolytics and Anticoagulants
6.11 Recombinant Protein
6.12 Others
7. Biopharmaceutical Market– By Therapeutic Application (Market Size - $Million/$Billion)
7.1 Oncology
7.2 Inflammatory Diseases
7.3 Cardiology
7.4 Neurology
7.5 Autoimmune Disorders
7.6 Metabolic Disorders
7.7 Hormonal Disorders
7.8 Others
8. Biopharmaceutical Market– By End Use (Market Size - $Million/$Billion)
8.1 Health and Care
8.2 Biopharmaceutical Companies
8.3 Diagnostic Labs
8.4 Clinical Research Institute
8.5 CROs
9. Biopharmaceutical Market- By Geography (Market Size - $Million/$Billion)
9.1 North America
9.1.1 U.S.
9.1.2 Canada
9.1.3 Mexico
9.2 Europe
9.2.1 U.K.
9.2.2 Germany
9.2.3 France
9.2.4 Italy
9.2.5 France
9.2.6 Netherlands
9.2.7 Spain
9.2.8 Rest of Europe
9.3 Asia-Pacific
9.3.1 China
9.3.2 Japan
9.3.3 South Korea
9.3.4 India
9.3.5 Australia & New Zealand
9.3.6 Rest of Asia-Pacific
9.4 Rest of the World
9.4.1 Middle East
9.4.2 Africa
9.4.3 South America
10. Biopharmaceutical Market Entropy
11. Biopharmaceutical Market Company Analysis
11.1 Company Revenue, Products, M&A, Developments
11.2 Company 1
11.3 Company 2
11.4 Company 3
11.5 Company 4
11.6 Company 5
11.7 Company 6
11.8 Company 7
11.9 Company 8
11.10 Company 9
11.11 Company 10
"*Financials for private companies would be provided on a best efforts basis”.
